The most outstanding
Grupo SURA posted USD 595 million in YTD net income at the end of Q3 2025
Publicado el 13 November 2025
Grupo SURA agreed to sell its stake in ARUS
Publicado el 24 November 2025
Grupo SURA moves forward with its debt management strategy with two credit operations for COP 1.8 trillion
Publicado el 09 September 2025
News Center
Construction begins on VaxThera plant to produce vaccines and biologicals for Colombia and the rest of the region
Publicado el 02 February 2022
Country Code Survey*
Publicado el 31 January 2022
Board Decisions*
Publicado el 27 January 2022
Grupo SURA advances with the payment of dividends 2022
Publicado el 03 January 2022
Clarification on the acceptance percentages corresponding to the tender offer for Grupo SURA shares*
Publicado el 30 December 2021
Colombia signs an agreement governing the co -development of vaccines using mRNA technology
Publicado el 16 December 2021